Avalo Therapeutics, Inc. (AVTX) is a Biotechnology company in the Healthcare sector, currently trading at $13.90. It has a SharesGrow Score of 43/100, indicating a mixed investment profile with 3 out of 7 criteria passed.
Analyst consensus target is AVTX = $45 (+220.1% upside).
Valuation: AVTX trades at a trailing Price-to-Earnings (P/E) of -2.5 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 0.18.
Financials: revenue is $59,000, -84.3%/yr average growth. Net income is $78M (loss), growing at -36.6%/yr. Net profit margin is -132642.4% (negative). Gross margin is -483.1% (-564.1 pp trend).
Balance sheet: total debt is $2M against $83M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 8.14 (strong liquidity). Debt-to-assets is 2.1%. Total assets: $116M.
Analyst outlook: 3 / 5 analysts rate AVTX as buy (60%) — moderate consensus.
SharesGrow 7-Criteria breakdown: Value 100/100 (Pass), Growth 15/100 (Fail), Past 0/100 (Fail), Health 100/100 (Pass), Moat 0/100 (Fail), Future 73/100 (Pass), Income 10/100 (Fail).
